Pembrolizumab improves survival in non-squamous NSCLC

被引：0
|
作者：
不详
机构：
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：1306 / 1306
页数：1
相关论文
共 50 条
  • [21] Effects on immunotherapy of EGFR mutation subtypes in non-squamous NSCLC.
    Tang, Haibo
    Li, Xiaoning
    Xie, Wenzhuan
    Huang, Mengli
    CANCER RESEARCH, 2021, 81 (13)
  • [22] ALK/EML4 translocation in non-squamous NSCLC and their predictors
    Dias, Margarida
    Linhas, Rita
    Antunes, Ana
    Campainha, Sergio
    Conde, Sara
    Barroso, Ana
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [23] Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
    Peters, Solange
    Cappuzzo, Frederico
    Horn, Leora
    Paz-Ares, Luis
    Borghaei, Hossein
    Barlesi, Fabrice
    Steins, Martin
    Felip, Enriqueta
    Spigel, David
    Dorange, Cecile
    Lu, Haolan
    Healey, Diane
    Sanchez, Teresa Kong
    Bhagavatheeswaran, Prabhu
    Novotny, James, Jr.
    Lestini, Brian
    Brahmer, Julie
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S253 - S253
  • [24] Promising targets and current clinical trials in metastatic non-squamous NSCLC
    Zer, Alone
    Leighl, Natasha
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [25] Clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC patients aged 75 years or older at US oncology practices
    Velcheti, V.
    Hu, X.
    Chen, X.
    Piperdi, B.
    Burke, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S856 - S856
  • [26] Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland
    Pardo, E.
    Barbier, M.
    Panje, C.
    Gautschi, O.
    Lupatsch, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S992 - S992
  • [27] Health-Related Quality of Life with Pembrolizumab or Placebo plus Pemetrexed plus Platinum in Non-Squamous NSCLC: KEYNOTE-189
    Garassino, M.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    Domine, M.
    Hochmair, M.
    Powell, S.
    Cheng, S.
    Bischoff, H.
    Peled, N.
    Reck, M.
    Hui, R.
    Garon, E.
    Boyer, M.
    Yang, J.
    Burke, T.
    Pietanza, M. C.
    Gandhi, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S155 - S155
  • [28] PERLA: Randomized Phase II Trial of Dostarlimab plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic Non-Squamous NSCLC
    Spira, A.
    Lim, S. M.
    Griesinger, F.
    De Marinis, F.
    Mccarthy, T.
    Huseinovic, N.
    O'Donnell, S.
    Ahn, J. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1013 - S1014
  • [29] Community experience of implementing carboplatin, pemetrexed and pembrolizumab treatment in the North East England population for non-squamous non-small cell lung cancer (NSCLC)
    Kohli, S.
    Greystoke, A.
    Gardiner, J.
    LUNG CANCER, 2020, 139 : S53 - S53
  • [30] Population-level impact of EGFR mutation testing in non-squamous NSCLC
    McKeage, M. J.
    Elwood, J. M.
    Tin, S. Tin
    Khwaounjoo, P.
    Aye, P.
    Li, A.
    Shepherd, P.
    Laking, G.
    Kingston, N.
    Lewis, C.
    Love, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345